Back to Pulmonology
Pulmonologyv2011Evidence-Based

du Bois Score for Idiopathic Pulmonary Fibrosis (IPF) Mortality

Determines 1-year mortality risk in IPF patients using PFT and clinical indicators. Developed from two clinical trials (n=1,099) to identify independent predictors of 1-year mortality in idiopathic pulmonary fibrosis.

Clinical Input Parameters

years
Range: 18 — 120 years
% predicted
Range: 10 — 150 % predicted
% predicted change
Range: -50 — 50 % predicted change
Clinical Assessment
Awaiting Parameters
du bois score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The du Bois Score for Idiopathic Pulmonary Fibrosis (IPF) Mortality is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within pulmonology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

du Bois Score = Age points + Respiratory hospitalization points + FVC % predicted points + FVC change points. Age: 51-60 years (1 pt), 61-70 years (2 pts), >70 years (3 pts). Recent respiratory hospitalization: Yes (2 pts). FVC % predicted: 50-65% (1 pt), <50% (2 pts). FVC decline >10% in 24 weeks: Yes (3 pts).

Clinical Pearls & Practice Notes

  • Developed from data of 1,099 IPF patients from two clinical trials to predict 1-year mortality.
  • Score ranges from 0-10 points with higher scores indicating increased mortality risk.
  • Age scoring: ≤50 years (0 pts), 51-60 years (1 pt), 61-70 years (2 pts), >70 years (3 pts).
  • Respiratory hospitalization in past 6 months: Yes (2 pts), No (0 pts).
  • FVC % predicted: >65% (0 pts), 50-65% (1 pt), <50% (2 pts).
  • FVC decline >10% over 24 weeks: Yes (3 pts), No (0 pts).
  • Higher scores correlate with increased 1-year mortality risk in IPF patients.
  • Should be used in conjunction with clinical judgment and other prognostic factors.
  • Consider lung transplantation evaluation for high-risk patients who are candidates.
  • Regular monitoring of pulmonary function tests is essential for IPF management.
  • This tool aids in prognosis assessment but does not replace comprehensive clinical evaluation.

Evidence & Literature Citations

  1. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(4):459-66. doi: 10.1164/rccm.201011-1790OC.
  2. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684-91. doi: 10.7326/0003-4819-156-10-201205150-00004.
  3. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824. doi: 10.1164/rccm.2009-040GL.

Score Interpretation Ranges

Low Risk0 – 4 pts

Low 1-year mortality risk

Intermediate Risk5 – 8 pts

Intermediate 1-year mortality risk

High Risk9 – 15 pts

High 1-year mortality risk

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.